BioStock: PHI charts a bold course to impact regenerative medicine

July 6, 2023
Language flag

Swedish medtech company PHI released its year-end report last week, outlining its transformative phase and strategic focus on regenerative medicine and clinical applications. To delve into the report’s highlights and shed light on the company’s vision and initiatives, BioStock contacted CEO Patrik Eschricht.

Read the full interview with Patrik Eschricht on biostock.se.

Latest News

Bulletin from extraordinary general meeting in Phase Holographic Imaging PHI AB (publ) 14 March 2024

On Thursday, March 14, 2024, Phase Holographic Imaging PHI AB (publ), held an extraordinary general meeting. The following resolutions were passed at the meeting.
blue-cells_white-bg_banner

Shaping the future of Regenerative Medicine – PHI’s vision for QPI in Cell Therapy Manufacturing

PHI presents a comprehensive opinion piece detailing the versatility and potential the Company sees for Quantitative Phase Imaging (QPI) technology in Regenerative Medicine. PHI outlines how QPI will offer enhanced cell quality control in the cell manufacturing process, thereby addressing a central puzzle piece for making cell-based therapies safe, affordable, and accessible for all.
Altium_logo

New Distributor Partner Manager at Altium set to enhance global sales for PHI

PHI is conveying the news that its global distributor, Altium ., has appointed a PHI-dedicated distributor partner manager. This strategic step is set to significantly enhance the reach and sales performance of PHI’s HoloMonitor technology on a global scale.
See All News